# Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

> **NCT01027364** · PHASE3 · COMPLETED · sponsor: **Bioverativ Therapeutics Inc.** · enrollment: 123 (actual)

## Conditions studied

- Severe Hemophilia B

## Interventions

- **DRUG:** Factor IX (rFIXFc)
- **DRUG:** rFIX

## Key facts

- **NCT ID:** NCT01027364
- **Lead sponsor:** Bioverativ Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2020-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01027364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01027364, "Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01027364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*